You just read:

TWi Biotechnology Announces Last Patient Enrolled in Phase 2 Proof-of-Concept Study of AC-203 for Treatment of Epidermolysis Bullosa

News provided by

TWi Biotechnology, Inc.

Jan 22, 2019, 08:23 ET